Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex
Open Access
- 10 June 2011
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 25 (9) , 3106-3114
Abstract
Duchenne muscular dystrophy (DMD) and limb girdle muscular dystrophy (LGMD) 2C‐F result from the loss of dystrophin and the sarcoglycans, respectively. Dystrophin, a cytoskeletal protein, is closely associated with the membrane‐bound sarcoglycan complex. Despite this tight biochemical association, the function of dystrophin and the sarcoglycan subunits may differ. The loss of dystrophin in skeletal muscle results in muscle that is highly susceptible to contraction‐induced damage, but the skeletal muscle of mice lacking γ‐ or δ‐sarcoglycan are less susceptible. Using mouse models of DMD, LGMD‐2C, and LGMD‐2F, we demonstrate that isolated cardiac myocytes from mice lacking either γ‐ or δ‐sarcoglycan have normal compliance. In contrast, dystrophin‐deficient myocytes display poor passive compliance and are susceptible to terminal contracture following mild passive extensions. Mice deficient in dystrophin and, less so, δ‐sarcoglycan have reduced survival during in vivo dobutamine stress testing compared to controls. Catheter‐based hemodynamic studies show deficits in both baseline and dobutamine‐stimulated cardiac function in all of the dystrophic mice compared to control mice, with dystrophin‐deficient mice having the poorest function. In contrast, histopathology showed increased fibrosis in the sarcoglycan‐deficient hearts, but not in hearts lacking dystrophin. In summary, this study provides important insights into the unique mechanisms of disease underlying these different models of inherited dystrophic cardiomyopathy and supports a model where dystrophin, but not the sarcoglycans, protects the cardiac myocyte against mechanical damage.—Townsend, D., Yasuda, S., McNally, E., Metzger, J. M. Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex. FASEB J. 25, 3106‐3114 (2011). www.fasebj.orgKeywords
Funding Information
- Muscular Dystrophy Association (68419)
This publication has 57 references indexed in Scilit:
- Upregulation of paxillin and focal adhesion signaling follows Dystroglycan Complex deletions and promotes a hypertensive state of differentiationEuropean Journal of Cell Biology, 2011
- Restoration of γ-Sarcoglycan Localization and Mechanical Signal Transduction Are Independent in Murine Skeletal MuscleJournal of Biological Chemistry, 2010
- Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx miceHuman Molecular Genetics, 2009
- Emergent Dilated Cardiomyopathy Caused by Targeted Repair of Dystrophic Skeletal MuscleMolecular Therapy, 2008
- Revised spectrum of mutations in sarcoglycanopathiesEuropean Journal of Human Genetics, 2008
- The 16 kDa subunit of vacuolar H+-ATPase is a novel sarcoglycan-interacting proteinBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2007
- Impact of sarcoglycan complex on mechanical signal transduction in murine skeletal muscleAmerican Journal of Physiology-Cell Physiology, 2006
- Evidence of early impairments in both right and left ventricular inotropic reserves in children with Duchenne's muscular dystrophyThe American Journal of Cardiology, 2004
- ON THE CLASSIFICATION, NATURAL HISTORY AND TREATMENT OF THE MYOPATHIESBrain, 1954
- The Pathology of Paralysis with Muscular Degeneration (Paralysie Myosclerotique), or Paralysis with Apparent HypertrophyBMJ, 1867